Collegium Pharmaceutical (COLL) Cost of Revenue: 2016-2025
Historic Cost of Revenue for Collegium Pharmaceutical (COLL) over the last 9 years, with Sep 2025 value amounting to $80.2 million.
- Collegium Pharmaceutical's Cost of Revenue rose 28.29% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.9 million, marking a year-over-year increase of 43.60%. This contributed to the annual value of $254.1 million for FY2024, which is 5.61% up from last year.
- Per Collegium Pharmaceutical's latest filing, its Cost of Revenue stood at $80.2 million for Q3 2025, which was up 0.72% from $79.6 million recorded in Q2 2025.
- Collegium Pharmaceutical's Cost of Revenue's 5-year high stood at $83.7 million during Q4 2024, with a 5-year trough of $28.7 million in Q4 2021.
- Moreover, its 3-year median value for Cost of Revenue was $62.5 million (2024), whereas its average is $66.8 million.
- In the last 5 years, Collegium Pharmaceutical's Cost of Revenue surged by 178.21% in 2022 and then crashed by 30.96% in 2023.
- Quarterly analysis of 5 years shows Collegium Pharmaceutical's Cost of Revenue stood at $28.7 million in 2021, then surged by 178.21% to $79.8 million in 2022, then crashed by 30.96% to $55.1 million in 2023, then skyrocketed by 51.79% to $83.7 million in 2024, then increased by 28.29% to $80.2 million in 2025.
- Its last three reported values are $80.2 million in Q3 2025, $79.6 million for Q2 2025, and $80.4 million during Q1 2025.